Repros Therapeutics Inc (NASDAQ:RPRX) riding on a testosterone Androxal high 76.34% - ABBV, LLY, AUXL

Repros riding on a testosterone Androxal high 76.34%

Northern, WI 04/01/2013 (avauncer) - The Repros Therapeutics Inc (NASDAQ:RPRX) (Current: $16.10, Up by 76.34%) ‘s testosterone stimulating drug Androxal was under trail and the company has announced very positive results. The drug still needs clearance from the regulators and investors are being wary and waiting it out. The testosterone market by itself is annually worth $2 billion and is on the ascent. This is primarily due to the fact the big pharmaceutical companies are spending and focusing in a big way on direct marketing. They have been targeting the male psyche with commercials that tout testosterone as a drug that every “manly” man needs to apply.

The creamy issue

All the current testosterone drugs are local applications and the AbbVie Inc (NYSE:ABBV) (Current: $42.78, Up by 1.57%) is supposed to have a concentration of 1.62% against the 1% that the creams by Eli Lilly & Co (NYSE:LLY) ( Current:$56.79, Up by 0.75%), Endo Health Solutions Inc (NASDAQ:ENDP) (Current: $30.76, Up by 0.07%) and Auxilium Pharmaceuticals, Inc (NASDAQ:AUXL) (Current: $17.29, Down by 2.04%) are selling in the market. However, this application has still to be avoided by children and women as even touching skin which has these creams on it can have a negative impact.

The unique one

The Repros Therapeutics Inc (NASDAQ:RPRX) advantage is that the drug is an oral medication. If it receives approval, the drug can easily rake in $500 million on an annual basis which is a quarter if the market.  The reason for the wariness on part of the investors is due to the fact that the third phase of the trial still has to be completed and the one that had already been completed has announced some issues. Androxal will have to go through a failure-free trial before it receives the nod from the FDA and the confidence of the investors.